Skip to content
Topics
Stories

The J&J rescue mission starts with a choice

People in this story

The Atlantic, May 2021

Had Johnson & Johnson’s COVID-19 vaccine been the first to get the FDA’s green light, it might have been hailed from the get-go for what it actually is: a scientific and technological marvel. It requires just one injection to confer full immunity—a boon for needlephobes and tough-to-reach populations who can’t easily access a second dose. It’s relatively cheap and has forgiving refrigeration requirements, making it a breeze to ship and store. And clinical trials showed that it’s a knockout at guarding against hospitalization and death, and 66 percent effective at preventing moderate to severe cases of COVID-19, even amid the rise of antibody-dodging coronavirus variants. Johnson & Johnson accomplished all this in less than a year, granting the world a safe and effective vaccine crucial to hastening the pandemic’s eventual end.

That’s not how the J&J story played out.

Continue reading at The Atlantic.

More Stories

Rash of mass shootings stirs US fears heading into summer

06.14.2021

Manhunts in Savannah, Chicago, Austin after weekend shooting rampages: ‘We do not want to be a police state’

06.14.2021

Hate crime laws won’t actually prevent anti-Asian hate crimes

06.15.21
In the News